Make like Great Gatsby at this intimate French Riviera hotel
Those words, from Fitzgerald's novel Tender is the Night, were probably written in this very spot. Back in 1925, when Fitzgerald was working on his novel, this hotel was a private villa that he rented for himself, his wife, Zelda, and daughter, Scottie.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
A Flash in the Pan: The Strange Story of Kodak's Ill-Fated Crypto Venture
Key Takeaways Eastman Kodak on Monday warned it could be forced to declare bankruptcy for the second time since 2012. Its last bankruptcy led the company to pursue licensing deals, one of which, in 2018, involved a blockchain-powered photo rights platform, KODAKOne, and associated cryptocurrency, KODAKCoin. KODAKCoin's private placements and initial coin offering, undertaken during 2018's crypto winter, were poorly received, and KODAKOne never launched in Kodak (KODK), after more than 100 years in business, may not be long for this world. The company issued a 'going concern' warning on Monday, informing investors it lacks the financing or adequate cash flow to pay debt that's coming due in the next 12 months. Kodak, once one of the largest companies in the world and a developer of cutting-edge technology, fell victim to the digitization of photography and, after years of declining sales, declared bankruptcy in 2012. It emerged from bankruptcy focused on printing technology and specialty chemicals while licensing its brand name on the side. That line of business roped it into a questionable venture in the world of cryptocurrency at what proved to be an inauspicious time. What Was KODAKOne? Kodak, in January 2018, announced a licensing agreement with the company WENN Digital, which agreed to launch KODAKOne, a platform through which photographers could use blockchain technology to manage and monetize their photos, and KODAKCoin, a native cryptocurrency. The platform was to be launched with the funds raised from a KODAKCoin initial coin offering, which began in May 2018. Kodak's licensing agreement reportedly gave it a minority stake in WENN Digital, 3% of all KodakCoins, and future royalties. The idea was that photographers would upload their photographs to KODAKOne, where they would license the images and use web-crawling software to flag copyright violations. Users would be paid in KODAKCoin for all business conducted on the platform. The rub: the KODAKCoin ICO, to comply with securities laws, was only open to accredited investors—anyone with a net worth of more than $1 million or annual income of $200,000 or more. So, photographers were to be paid in a cryptocurrency that could only be used to pay for services on the platform, which KODAKOne said would eventually include a marketplace for the sale and rental of equipment or studio space. But if they wanted to convert any of that KODAKCoin into dollars, they would need to find a rich person to buy it. That may not have been an issue if KODAKCoin took off in its ICO, but its reception was lukewarm at best. According to the project's confidential offering memorandum, which cryptocurrency blogger David Gerard acquired and published in the midst of the ICO, an early 2018 private placement raised just $880,000 of the $6.75 million that was expected. Bad Idea Meets Bad Timing Kodak's attempt to jump on the crypto train appeared fruitful at first. Shares tripled in value in the days after the January 8 announcement. Unfortunately for Kodak, its foray into digital assets coincided with the onset of crypto winter—the cyclical slump in crypto markets that tends to follow periods of speculative frenzy. The price of bitcoin slid from a record high of more than $20,000 in late 2017 to less than $4,000 in December 2018. In October 2018, KODAKOne launched a beta version of its licensing portal, which reportedly generated $1 million in licensing claims in its first two months. But the portal never exited beta mode, nor was KODAKCoin ever integrated with the platform. The last time Kodak mentioned the project was in August 2019, when it noted the volatility of the cryptocurrency market could pose a risk to its stock price. By the time of its third-quarter earnings report in November, crypto was no longer a risk. According to Gerber, KODAKOne's web domain was effectively shut down in late 2020. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Asante Gold raises $172m and completes Kinross restructuring
Asante Gold has raised C$237m in proceeds through a private placement and completed the restructuring of its obligations to Kinross Gold. The private placement involved the sale of 163.3 million subscription receipts at C$1.45 each, with the proceeds now released to Asante Gold following the satisfaction of escrow conditions. This move is part of a broader $500m financing package aimed at advancing the company's mining projects. The equity offering is part of the first stage of the financing package, which includes a $125m mezzanine facility, a $50m gold stream, a $10m non-brokered private placement and a $5m draw from the senior debt facility, all expected to close by 15 August 2025. The subscription receipts have been converted into common shares, subject to a four-month statutory hold period applicable to Canadian securities laws, which expires on 8 November 2025. Asante Gold has also granted Appian Capital Advisory 16.2 million non-transferrable common share purchase warrants as part of Appian's advisory role related to $175m of the financing package. These warrants, with an exercise price of C$1.67, are valid until 11 August 2029 and subject to a four-month hold period ending on 12 December 2025. Additionally, as per the Kinross Agreement dated 11 August 2025, Asante Gold has restructured its debts to Kinross by making a cash payment of $53m, issuing 36.9 million common shares and providing an $80m convertible debenture. In connection with the agreement, Kinross has also adjusted its security interests in the Chirano Mine, now subordinate to the senior lenders' security package. The net proceeds from the equity offering and financing package will be used for development and growth at the Bibiani and Chirano mines, the cash payment to Kinross, retiring short-term liabilities and general working capital. This development follows Asante Gold's announcement in January of accelerated operations at the Bibiani Mine, supported by a $100m gold forward sale to support expanded operations. "Asante Gold raises $172m and completes Kinross restructuring" was originally created and published by Mining Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
